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Mutations in the serine palmitoyltransferase subunit 1 (SPTLC1) gene are the most common cause of
hereditary sensory neuropathy type 1 (HSN1). Here we report the clinical and molecular consequences of
a particular mutation (p.S331Y) in SPTLC1 affecting a patient with severe, diffuse muscle wasting and
hypotonia, prominent distal sensory disturbances, joint hypermobility, bilateral cataracts and consider-
able growth retardation. Normal plasma sphingolipids were unchanged but 1-deoxy-sphingolipids were
signiﬁcantly elevated. In contrast to other HSN patients reported so far, our ﬁndings strongly indicate
that mutations at amino acid position Ser331 of the SPTLC1 gene lead to a distinct syndrome.
 2013 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Hereditary sensory neuropathies (HSN) are clinically and genet-
ically heterogeneous disorders of autosomal dominant or autosomal
recessive inheritance characterized by axonal atrophy and degen-
eration, predominantly affecting the sensory neurons [1e3]. Hall-
mark features of the dominantly inherited variant subclassiﬁed as
HSN type 1 (HSN1) comprise severe distal sensory loss, painless
injuries, skin ulcers and frequent bone infections that sometimes
necessitate amputations of toes or feet [1e3]. Disease onset is usu-
ally in early adulthood. Variable distalmuscleweakness andwastings, Medical University Vienna,
43 1 40 400 4029.
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der CC BY-NC-ND license.and lancinatingpain is also often observed.With diseaseprogression
the hands may become involved similarly [1e3]. Mutations in the
serine-palmitoyltransferase, long chain base subunit 1 (SPTLC1) gene
are themost frequent cause of HSN1 [4,5]. SPTLC1 encodes one of the
three subunits of serine palmitoyltransferase (SPT), which catalyzes
the ﬁrst step in the de-novo synthesis of sphingolipids which is the
condensation of L-serine and palmitoyl-coenzyme A. Under certain
conditions SPT shows a shift from its canonical substrate L-serine to
the alternative substrates L-alanine and glycine which leads to the
formation of an atypical class of 1-deoxy-sphingolipids (1-deoxySL).
Low levels of 1-deoxySLs are typically present in plasma of healthy
individuals. Pathologically elevated 1-deoxySLs have been found in
transgenic HSN1 mouse models and in HSN1 patients carrying
different SPTLC1mutationsbut also in individualswith themetabolic
syndrome and diabetes [6e8]. The 1-deoxySLs show pronounced
neurotoxic effects in vitro and may be disease causing in HSN1 but
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athy. The observation that a high dose L-serine supplementation
lowers plasma 1-deoxySL levels in HSN1 patients and in the trans-
genicmousemodel has encouraged our hopes for aﬁrst treatment of
this ulcero-mutilating disorder. This emphasizes the importance of
an early andaccurate genetic diagnosis ofHSN1patients [9]. Herewe
report a novel SPTLC1 mutation in a female patient exhibiting an
unusually severe and complicated phenotype. We show that muta-
tions at the particular amino acid position Serine 331 (S331) are
associated with a distinct syndromic phenotype in comparison to
previously reported mutations in HSN1.
2. Patient and methods
The female proband was the ﬁrst child of non-consanguineous
and healthy parents. Pregnancy was normal but she was born by
cesarean delivery three weeks early. Motor milestones during the
ﬁrst years were normal but height and weight always ranked low in
percentile or theywere even below the lower limit. At 4 years of age
a strange gait, frequent falls andmoderate hand tremor were noted.
Sensory disturbances were initially mild but progressed with dis-
ease. Considerable pes cavus foot deformity necessitated tripleFig. 1. Clinical features of the patient. Diffuse muscle hypotrophy and hypermobility of join
after burns due to reduced pain and temperature sensation.arthrodesis at age 5. Subsequently, the diagnosis of hereditary
motor and sensory neuropathy (HMSN) was made. Disease pro-
gressionwas rapid and soonmuscle weakness and wasting affected
upper limbs, but also proximal limb and trunkmuscles thus leading
to severe scoliosis, respiratory problems and wheelchair depen-
dence at age 14. In addition, there was prominent growth retar-
dation and delayed puberty whereas intellectual development was
normal. At age 13, bilateral cataracts were diagnosed and surgically
treated.
On examination at age 12 years there was general muscle
hypotrophy and hypotonia with pronounced weakness in the distal
muscles of the upper and lower limbs (Fig. 1). There were promi-
nent sensory disturbances which were pronounced in the feet and
affected all qualities except for the vibration sense which remained
completely preserved. At the toes scars after burns due to reduced
prominent pain and temperature sensation were evident (Fig. 1,
arrow). Hypermobility of the joints, bilateral hand tremor and
fasciculations, which were most prominent in the tongue, were
observed (Fig. 1). Tendon reﬂexes were brisk but the Babinski sign
was negative.
Further evaluation included nerve conduction studies (NCS),
magnetic resonance imaging (MRI) studies and molecular geneticts in the patient carrying the p.S331Y SPTLC1 mutation. Note scars at the toes (arrow)
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was performed on a Genome Analyzer HiSeq 2000 system (Illumina,
San Diego, CA.). Methods and parameters were used as shown pre-
viously [10]. The plasma sphingoid base proﬁle and cellular SPT ac-
tivity was analyzed as described previously [11]. The study was
approved by the local ethical committee.
3. Results
Nerve conduction velocities in the upper limbs were within
the intermediate range (median motor: 32 m/s, median sensory:
39 m/s, SNAP: 16.7 mV) and compound motor action potentials
(CMAP: 2.5 mV, peakepeak) were reduced. There was no response
for motor or sensory nerves in the lower limbs. Based on these
results the patient was initially classiﬁed as HMSN type II. MRI of
the brain and spinal cord was normal at the age of 9 years. Endo-
crinological examination of the patient did not reveal any addi-
tional disturbances.
After exclusion of mutations in all common HMSN and SCA
(spino-cerebellar ataxia) genes, whole exome sequencing was car-
ried out. Thereby, a heterozygous missense change in SPTLC1
(c.992G- > T; p.S331Y) was detected and conﬁrmed by Sanger re-
sequencing. The parents were normal on neurological and on
electrophysiological examination and this change was absent in
both of them. Also, no sequence variation at aa position S331 was
found in 1969 individuals from our in-house exomes.Fig. 2. a) 1-DeoxySL levels in plasma samples of the patient carrying the p.S331Y mutation,
increased in the plasma of the S331Y patient but not in the plasma of the unaffected paren
patients and controls (data not shown). b) De-novo generation of sphinganine and 1-deo
signiﬁcantly reduced canonical SPT activity and a signiﬁcantly increased formation of 1-deo
formation was about 30% lower for the S331Y than for the S331F mutation (**p < 0.05).Subsequently, wemeasured the 1-deoxySL levels in the patients’
plasma which were found to be signiﬁcantly elevated (Fig. 2a).
Increased 1-deoxySL formationwas also conﬁrmed in HEK293 cells
expressing the p.S331F and p.S331Ymutant (Fig. 2b). In comparison
1-deoxySL formation was lower in the p.S331Y than in the previ-
ously reported p.S331F mutant. Canonical serine activity was
reduced by 60% in both mutants.
4. Discussion
To date, six disease causing mutations in SPTLC1 (p.C133W,
p.C133Y, p.C133R, p.V144D, p.S331F, p.A352V) have been
described [5]. SPLTC1 mutations at positions p.C133, p.C144 and
p.A352 result in the typical HSN1 phenotype [5,12]. In contrast,
the p.S331F mutation, which was reported in two patients only,
occurred de-novo and was associated with an extraordinary severe
and complicated phenotype. One of these patients was initially
diagnosed as early onset HMSN type II due to muscle weakness
and hypotrophy in addition to prominent sensory disturbances,
bone fractures and osteomyelitis. Notably, this patient also
developed juvenile cataract at age of 9 years, complete retinal
detachment at 10 and repetitive corneal ulceration and keratitis
with poor corneal healing [13]. An even more complex congenital
phenotype with severe growth retardation, global amyotrophy,
hypotonia, joint hyperlaxity, vocal cord paralysis, bilateral cata-
ract, mild mental retardation, microcephaly and respiratoryfamily members and controls. The levels of the 1-deoxy-sphiglipids were signiﬁcantly
ts or unrelated healthy controls. Total sphingolipid levels were not different between
xy-sphinganine. HEK293 cells expressing either the S133F or S331Y mutant show a
xy-sphinganine in comparison to SPTLC1wt expressing cells. The 1-deoxy-sphinganine
Table 1
Core features of the syndromic phenotype produced by the S331 SPTLC1 mutation.
Reported clinical features
as part of the S331eSPTLC1
syndrome
Huehne
et al., 2008
[13] (p.S331F)
Rotthier
et al., 2009
[5] (p.S331F)
This study
(p.S331Y)
Diffuse muscle hypotrophy Yes Yes Yes
Growth retardation nm Yes Yes
Motor and sensory neuropathy Yes Yes Yes
Foot ulcers, amputations
and/or burns
Yes Yes Yes
Juvenile cataracts Yes Yes Yes
Mental retardation nm Yes No
Joint hypermobility nm Yes Yes
Vocal cord paralysis nm Yes No
Tremor nm nm Yes
Fasciculations nm nm Yes
Other ocular manifestations Yes nm No
Respiratory problems nm Yes Yes
Features present in at least two patients are highlighted in bold (nm: not
mentioned).
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nicity of the p.S331F mutation was conﬁrmed by functional
studies: in vitro a reduction of SPT activity was shown and in
plasma samples of both patients increased levels of 1-deoxySLs
were detected [9]. Nevertheless, it remained uncertain whether
these additional features were also related to the p.S331F muta-
tion [12]. The patient reported here carries a novel mutation in
SPTLC1 leading to a change of serine to tyrosine at aa position 331
which also results in a similar unusually severe and complicated
phenotype.
The core phenotype of the three patients described so far
carrying an S331 SPTLC1 mutation resembles early onset HMSN.
The additional features highly enlarge the phenotype of HSN1 but
are rather unique between the three patients (Table 1) thus
proposing the existence of a distinct and severe syndrome asso-
ciated with this particular mutation. Since oral L-Serine supple-
mentation has been suggested to be a future treatment option, it
will be most important to achieve a quick diagnosis by early
screening of exon 11 of SPTLC1 in patients exhibiting this distinct
phenotype.Acknowledgement
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